No, Zetia (ezetimibe) does not help with dementia and is not indicated for cognitive impairment or dementia treatment.
Zetia is FDA-approved exclusively for lowering cholesterol, not for treating or preventing dementia. The FDA drug label makes no mention of cognitive benefits, dementia treatment, or neuroprotective effects 1. The established dementia treatment guidelines focus on cholinesterase inhibitors and memantine—not cholesterol-lowering agents like ezetimibe 2.
Why This Question Arises
The confusion likely stems from the cholesterol-dementia hypothesis, since elevated cholesterol has been linked to cognitive decline. However, lowering cholesterol with ezetimibe has not been proven to improve cognitive outcomes in humans with dementia.
The Evidence Breakdown
FDA-Approved Indications
Ezetimibe is approved only for:
- Reducing LDL cholesterol in hyperlipidemia
- Cardiovascular risk reduction when combined with statins 1
There is zero mention of cognitive function, dementia prevention, or neuroprotection in the official drug labeling.
Guideline Recommendations
The 2020 Canadian Consensus Conference on Dementia—the most authoritative recent guideline—recommends only:
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for AD, PDD, DLB, and vascular dementia
- Memantine for moderate-to-severe dementia 2
Ezetimibe is completely absent from dementia treatment algorithms.
Research Evidence: Promising But Preliminary
While one recent study suggests ezetimibe may reduce ADRD risk by lowering protein aggregation (particularly the HK1::14-3-3G interaction), this is early-stage mechanistic research 3. The study shows:
- Potential disruption of pathological protein aggregation in cell and nematode models
- Database mining suggesting reduced dementia risk (OR 0.14, P<0.0001)
- However, this is NOT a randomized controlled trial in humans with dementia
An older 2009 mouse study showed memory improvement in high-fat diet and streptozotocin-induced dementia models 4, but animal models do not translate reliably to human dementia treatment.
Critical Limitations
- No large-scale randomized controlled trials in humans with dementia
- No FDA approval or guideline endorsement for cognitive indications
- The 2025 stroke study 5 addresses recurrent ischemic stroke, not dementia
- The antidepressant study 6 is irrelevant to ezetimibe
Clinical Bottom Line
Do not prescribe ezetimibe for dementia treatment or cognitive decline. If a patient has both hyperlipidemia and dementia:
- Treat the hyperlipidemia with ezetimibe if indicated for cardiovascular risk
- Treat the dementia with evidence-based cognitive enhancers (cholinesterase inhibitors, memantine) per guidelines 2
- Do not expect cognitive benefits from cholesterol lowering alone
Common Pitfall to Avoid
Do not conflate cardiovascular risk reduction with dementia treatment. While vascular risk factors contribute to dementia, no cholesterol-lowering drug—including ezetimibe—has proven efficacy for treating established dementia or reversing cognitive decline in clinical practice.
If future large-scale RCTs demonstrate cognitive benefits, recommendations may change, but current evidence does not support using ezetimibe for dementia.